＜5026＞ Triple Eyes 1172 +107
Significant backlash. The adoption of the face recognition attendance system “AIZE” by the Setagaya-ku district of Tokyo, which was disclosed on the 22nd, is once again viewed as a purchase material. This is the first time a large municipality has adopted the same system. It is also well received that the group company won first place for 3 consecutive years in terms of domestic mining machine (computer for mining cryptographic assets) sales volume, number of customers, and number of customers operating in-house data centers the day before. Since the stock price had fallen after the year-to-date high was recorded on the 23rd, it seems that there is also a rush to buy.
＜176A＞ resyl 1097 -43
Significantly cheaper. It was listed the day before and the initial price was set at 1205 yen, then it closed and fell. Today's initial public offering (IPO) following Cojin Bio ＜177A＞, which was listed on this day, is about 1 month from now, and the brunt of searching was headed as a recent IPO brand, and buying from a sense of temporary price was dominant, but the price gradually disappeared, and it ended by breaking the previous day's closing price.
＜4498＞ Cybertrust 1631 -134
Significant decline for the first time in 4 days. The operating profit forecast for the fiscal year ending 25/3 has been announced as 1,300 billion yen, up 16.9% from the previous fiscal year. The certification/security service “iTrust” and the like are expected to drive growth. Operating profit for the fiscal year ended March 24 increased 5.5% to reach 1,112 billion yen. However, in addition to being pushed by a downward trend in the overall market price, the fact that net profit fell 28.5% to 518 million yen and fell below the company plan (740 million yen) due to recording impairment losses is disgusting, and sales have become dominant.
＜5131＞ Linkers 225 +5
The price has been high since the beginning of the year. The fact that it was announced on the 23rd that they would partner with Ondec ＜7360＞ in the M&A business continued to be viewed as buying material. In addition to collaborating in the M&A advisory business, platform development cooperation and Linkers' SaaS type business matching system will be introduced to OnDc. Ondec stocks also update their year-to-date highs every day.
＜9158＞ CUC 1790 -387
Low price since listing. The operating profit forecast for the fiscal year ending 25/3 has been announced to be 4.0 billion yen, up 7.0% from the previous fiscal year. An increase in 50-bed facilities with relatively high profit margins in the hospice segment is expected to contribute. Meanwhile, since the impact of exchange gains that occurred in the previous fiscal year has declined, the net profit forecast is 2.200 billion yen, down 15.2%. Operating profit for the fiscal year ended March 24 rose 1.5% to reach 3.737 billion yen. The medical institution segment and hospice segment grew, and an increase in profit was secured.
＜2342＞ Trans G 263 +38
Significantly higher. The operating profit and loss forecast for the fiscal year ending 24/3 has been revised upward from the previous deficit of 50 million yen to a surplus of 90 million yen (deficit of 0.25 million yen in previous fiscal year results). The performance of the drug discovery support business was improved by thoroughly reinforcing ready-to-work personnel and managing delivery dates. Also, in addition to the fact that price revisions based on the continuation of the depreciation trend of yen and the rise in product procurement costs have progressed in the investment/consulting business, it is expected that improvements have been seen in consumer purchasing motivation even at subsidiaries that operate e-commerce, contributing to the surplus transition.